Cargando…
Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains
Systemic light chain (AL) amyloidosis is a fatal protein misfolding disease in which excessive secretion, misfolding, and subsequent aggregation of free antibody light chains eventually lead to deposition of amyloid plaques in various organs. Patient-specific mutations in the antibody V(L) domain ar...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7949129/ https://www.ncbi.nlm.nih.gov/pubmed/33508322 http://dx.doi.org/10.1016/j.jbc.2021.100334 |
_version_ | 1783663496699838464 |
---|---|
author | Rottenaicher, Georg J. Weber, Benedikt Rührnößl, Florian Kazman, Pamina Absmeier, Ramona M. Hitzenberger, Manuel Zacharias, Martin Buchner, Johannes |
author_facet | Rottenaicher, Georg J. Weber, Benedikt Rührnößl, Florian Kazman, Pamina Absmeier, Ramona M. Hitzenberger, Manuel Zacharias, Martin Buchner, Johannes |
author_sort | Rottenaicher, Georg J. |
collection | PubMed |
description | Systemic light chain (AL) amyloidosis is a fatal protein misfolding disease in which excessive secretion, misfolding, and subsequent aggregation of free antibody light chains eventually lead to deposition of amyloid plaques in various organs. Patient-specific mutations in the antibody V(L) domain are closely linked to the disease, but the molecular mechanisms by which certain mutations induce misfolding and amyloid aggregation of antibody domains are still poorly understood. Here, we compare a patient V(L) domain with its nonamyloidogenic germline counterpart and show that, out of the five mutations present, two of them strongly destabilize the protein and induce amyloid fibril formation. Surprisingly, the decisive, disease-causing mutations are located in the highly variable complementarity determining regions (CDRs) but exhibit a strong impact on the dynamics of conserved core regions of the patient V(L) domain. This effect seems to be based on a deviation from the canonical CDR structures of CDR2 and CDR3 induced by the substitutions. The amyloid-driving mutations are not necessarily involved in propagating fibril formation by providing specific side chain interactions within the fibril structure. Rather, they destabilize the V(L) domain in a specific way, increasing the dynamics of framework regions, which can then change their conformation to form the fibril core. These findings reveal unexpected influences of CDR-framework interactions on antibody architecture, stability, and amyloid propensity. |
format | Online Article Text |
id | pubmed-7949129 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society for Biochemistry and Molecular Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-79491292021-03-19 Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains Rottenaicher, Georg J. Weber, Benedikt Rührnößl, Florian Kazman, Pamina Absmeier, Ramona M. Hitzenberger, Manuel Zacharias, Martin Buchner, Johannes J Biol Chem Research Article Systemic light chain (AL) amyloidosis is a fatal protein misfolding disease in which excessive secretion, misfolding, and subsequent aggregation of free antibody light chains eventually lead to deposition of amyloid plaques in various organs. Patient-specific mutations in the antibody V(L) domain are closely linked to the disease, but the molecular mechanisms by which certain mutations induce misfolding and amyloid aggregation of antibody domains are still poorly understood. Here, we compare a patient V(L) domain with its nonamyloidogenic germline counterpart and show that, out of the five mutations present, two of them strongly destabilize the protein and induce amyloid fibril formation. Surprisingly, the decisive, disease-causing mutations are located in the highly variable complementarity determining regions (CDRs) but exhibit a strong impact on the dynamics of conserved core regions of the patient V(L) domain. This effect seems to be based on a deviation from the canonical CDR structures of CDR2 and CDR3 induced by the substitutions. The amyloid-driving mutations are not necessarily involved in propagating fibril formation by providing specific side chain interactions within the fibril structure. Rather, they destabilize the V(L) domain in a specific way, increasing the dynamics of framework regions, which can then change their conformation to form the fibril core. These findings reveal unexpected influences of CDR-framework interactions on antibody architecture, stability, and amyloid propensity. American Society for Biochemistry and Molecular Biology 2021-01-26 /pmc/articles/PMC7949129/ /pubmed/33508322 http://dx.doi.org/10.1016/j.jbc.2021.100334 Text en © 2021 Elsevier Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Article Rottenaicher, Georg J. Weber, Benedikt Rührnößl, Florian Kazman, Pamina Absmeier, Ramona M. Hitzenberger, Manuel Zacharias, Martin Buchner, Johannes Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains |
title | Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains |
title_full | Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains |
title_fullStr | Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains |
title_full_unstemmed | Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains |
title_short | Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains |
title_sort | molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7949129/ https://www.ncbi.nlm.nih.gov/pubmed/33508322 http://dx.doi.org/10.1016/j.jbc.2021.100334 |
work_keys_str_mv | AT rottenaichergeorgj molecularmechanismofamyloidogenicmutationsinhypervariableregionsofantibodylightchains AT weberbenedikt molecularmechanismofamyloidogenicmutationsinhypervariableregionsofantibodylightchains AT ruhrnoßlflorian molecularmechanismofamyloidogenicmutationsinhypervariableregionsofantibodylightchains AT kazmanpamina molecularmechanismofamyloidogenicmutationsinhypervariableregionsofantibodylightchains AT absmeierramonam molecularmechanismofamyloidogenicmutationsinhypervariableregionsofantibodylightchains AT hitzenbergermanuel molecularmechanismofamyloidogenicmutationsinhypervariableregionsofantibodylightchains AT zachariasmartin molecularmechanismofamyloidogenicmutationsinhypervariableregionsofantibodylightchains AT buchnerjohannes molecularmechanismofamyloidogenicmutationsinhypervariableregionsofantibodylightchains |